A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Latest Information Update: 29 Mar 2023
At a glance
- Drugs AS 012 (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries
- 23 Mar 2023 Status changed from active, no longer recruiting to completed.
- 19 Oct 2022 Planned End Date changed from 1 Jan 2023 to 1 Feb 2023.
- 06 May 2022 Planned End Date changed from 1 May 2023 to 1 Jan 2023.